Supernus Pharmaceuticals | SUPN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 6.54B 625M 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Aurora Cannabis CAD 46.62M 14.33M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Canopy Growth CAD 21.47M 434K 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 199.58M 3.46M 2025-12
Eisai JPY 168.85B 17.02B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Novo Nordisk DKK 64.01B 1.19B 2025-06
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Xeris Pharmaceuticals USD 72.15M 8.77M 2025-12